Literature DB >> 30068225

Mild Cognitive Impairment in Clinical Practice: A Review Article.

Sukanya Jongsiriyanyong1, Panita Limpawattana2.   

Abstract

The spectrum of cognitive decline in the elderly ranges from what can be classified as normal cognitive decline with aging to subjective cognitive impairment to mild cognitive impairment (MCI) to dementia. This article reviewed the up-to-date evidence of MCI including the diagnostic criteria of MCI due to Alzheimer's disease, vascular cognitive impairment and MCI due to Parkinson disease, management and preventive intervention of MCI. There are various etiologies of MCI, and a large number of studies have been conducted to ascertain the practical modalities of preserving cognition in predementia stages. Lifestyle modification, such as aerobic exercise, is an approved modality to preserve cognitive ability and decrease the rate of progression to dementia, as well as being recommended for frailty prevention.

Entities:  

Keywords:  Alzheimer’s disease; MCI; cognitive impairment; frailty; geriatric syndrome; minor neurocognitive disorder; predementia

Mesh:

Year:  2018        PMID: 30068225     DOI: 10.1177/1533317518791401

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  40 in total

1.  Cost-effectiveness Analysis of Combined Physical and Cognitive Exercises Programs Designed for Preventing Dementia among Community-dwelling Healthy Young-old Adults.

Authors:  Gohei Kato; Takehiko Doi; Hidenori Arai; Hiroyuki Shimada
Journal:  Phys Ther Res       Date:  2022-06-10

Review 2.  Ellagic Acid: A Dietary-Derived Phenolic Compound for Drug Discovery in Mild Cognitive Impairment.

Authors:  Wenjun Wang; Shaohui Wang; Yue Liu; Xiaobo Wang; Jia Nie; Xianli Meng; Yi Zhang
Journal:  Front Aging Neurosci       Date:  2022-07-04       Impact factor: 5.702

3.  Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms.

Authors:  Xinting Ge; Yuchuan Qiao; Jiyoon Choi; Rema Raman; John M Ringman; Yonggang Shi
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

4.  Discussing Mild Cognitive Impairment.

Authors:  Kristina Purganan
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-07-09

5.  Multimodal measurement approach to identify individuals with mild cognitive impairment: study protocol for a cross-sectional trial.

Authors:  Bernhard Grässler; Fabian Herold; Milos Dordevic; Tariq Ali Gujar; Sabine Darius; Irina Böckelmann; Notger G Müller; Anita Hökelmann
Journal:  BMJ Open       Date:  2021-05-25       Impact factor: 2.692

Review 6.  Sexuality and Neurodegenerative Disease: An Unmet Challenge for Patients, Caregivers, and Treatment.

Authors:  Mohamed Eshmawey
Journal:  Neurodegener Dis       Date:  2022-01-18       Impact factor: 2.977

7.  Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer's disease: new biomarkers for diagnosis and disease progression?

Authors:  Rosa Maria Corbo; Rita Businaro; Daniela Scarabino
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

8.  Comparison of Montreal Cognitive Assessment in Korean Version for Predicting Mild Cognitive Assessment in 65-Year and Over Individuals.

Authors:  Chiang-Soon Song; Hye-Sun Lee; Byung-Yoon Chun
Journal:  Occup Ther Int       Date:  2022-04-19       Impact factor: 1.565

9.  Clinical and demographic parameters predict the progression from mild cognitive impairment to dementia in elderly patients.

Authors:  Giovanni Zuliani; Michele Polastri; Tommaso Romagnoli; Lisa Marabini; Davide Seripa; Carlo Cervellati; Amedeo Zurlo; Angelina Passaro; Gloria Brombo
Journal:  Aging Clin Exp Res       Date:  2020-09-12       Impact factor: 3.636

10.  Lung function, COPD and cognitive function: a multivariable and two sample Mendelian randomization study.

Authors:  Daniel H Higbee; Raquel Granell; Gibran Hemani; George Davey Smith; James W Dodd
Journal:  BMC Pulm Med       Date:  2021-07-22       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.